About Jean-Claude Tardif
Jean-Claude Tardif is the Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal Pfizer-endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC).
Dr. Tardif has published more than 760 scientific articles and is a world leader in cardiovascular clinical trials, precision medicine and biomarkers studies. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases. Dr. Tardif and his team have created the MHICC, the Montreal Heart Institute longitudinal hospital genetic cohort, one of the largest hospital cohorts in the world (>22,000 subjects), the Beaulieu Saucier Pharmacogenomics Centre at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine (CEPMed), the latter funded by the Network of Centers of Excellence of Canada and which is also supported by multiple pharmaceutical and biotechnological companies.
His most recent research breakthroughs include the COLCOT trial which led to a repositioning of the readily available and inexpensive generic drug colchicine to reduce the risk of ischemic cardiovascular events after myocardial infarction, as well as the demonstration of dalcetrapib’s benefits in patients with a specific genetic profile with acute coronary syndrome. In addition to his many scientific contributions, Dr. Tardif acts as a reviewer for 25 peer-reviewed journals including The Journal of the American Medical Association, The Lancet, Circulation and more.